Electrovac AG and Rakovina Therapeutics receive new equity research ratings

BankM AG has issued a research update for electrovac AG, maintaining a ‘Buy’ rating with a 12-month target price of €14.18. The company reported fiscal year 2025/26 results with revenue of €118 million, a 20% increase, and EBIT of €14.0 million, a 54% increase, exceeding previous expectations. For Q1 2026/27, revenue reached €31.5 million, representing 12% growth.

Separately, First Berlin Equity Research GmbH has downgraded Rakovina Therapeutics Inc. from ‘Buy’ to ‘Add,’ significantly reducing the 12-month target price from CAD 4.00 to CAD 0.25. While the company has made scientific progress in its AI-supported preclinical pipeline—specifically with the kt-5000 program showing potential in tumor efficacy and brain penetration—the kt-2000-PARP1 program has reportedly fallen behind expectations.